AWARDS & RECOGNITIONS
Group BPCE Innovation Prize
🏅 Rosetta Omics is an innovation prize winner 🏆 Out of more than 50 great startup candidates led by ESCP Business School ESCP Alumni, we are happy to win this honorary innovation prize from Groupe BPCE Thank you ESCP Foundation Blue Factory ESCP AGORA ESCP Student Union and ESCP Business School and all jury members. We are very proud to be a winner of this innovation prize especially that Rosetta Omics was born at ESCP Business School and has been and still receiving a great support from ESCP community. ESCP Executive Education & Business Solutions Jean-Baptiste Say Institute – ESCP Business School Rosetta Omics will keep innovating and inspiring others to innovate!
Young Innovative Company (JEI)
We are very happy to announce that Rosetta Omics has just been officially awarded the status of Young Innovative Company (JEI)! This recognition values our ongoing commitment to research and development, particularly in the fields of precision medicine, oncology, artificial intelligence and multiomics technologies. It reflects our determination to innovate and provide ever more impactful solutions to patients, clinicians and all our partners. This status also opens up attractive tax advantages for our current and future investors, allowing them to benefit from specific tax incentives. A great opportunity to support innovation while optimizing your investment! The JEI status is a mark of confidence from the French State, rewarding the involvement of our entire team and paving the way for new growth prospects.
HTIDs1st European Innovation Prize
We are honored and thrilled to announce that Rosetta Omics has won the 1st 🥇 place among a seleted top 20 European companies at the 6th edition of the HealthTech Innovation Days (hashtag#HTIDs) organized by HealthTech For Care in Paris, France. Competing against some of the most innovative companies in Europe, this recognition is a powerful validation of the groundbreaking work we are doing to advance healthcare. We are incredibly grateful for the positive feedback we received from the esteemed jury, composed of top Key Opinion Leaders (KOLs) in healthcare, and the attendees at the event. This award is not just a milestone for our company—it is a testament to the value we’re developing for patients and the broader healthcare ecosystem.
Bio Partnering Pass Challenge
Very proud to be among the winners and be part of this amazing delegation of bright french startups. Thank you very much Medicen Paris Region and and Spartners by Servier France and BioLabs France for the opportunity. We appreciate it.
Hello Tomorrow’s Deep Tech Pioneers!
We are very happy to announce that Rosetta Omics have been named one of Hello Tomorrow’s Deep Tech Pioneers! 🌍 The email reads : “Congratulations !! We’re excited to announce that your groundbreaking venture, Rosetta Omics, has been selected as one of the esteemed Hello Tomorrow Deep Tech Pioneers! This prestigious recognition marks a pivotal moment in your journey to transform the world through innovation. Out of 4,600 applications from 120 countries, your project distinguished itself as a leading light in deep tech. As a Deep Tech Pioneer, you’ll gain exclusive, year-round access to a wealth of opportunities within our dynamic community”. ✨ Join us at the 10th Hello Tomorrow Global Summit on March 13-14, 2025, in Paris and connect with the world’s top innovators, industry leaders, investors, and deep tech visionaries. This summit is where groundbreaking ideas meet powerful networks—let’s shape the future of deep tech together!
Grant by Bpifrance
We are pleased to announce that Rosetta Omics has received the Bpifrance grant : BFT emergence to finance its deeptech program: two POCs studies in two solid tumors. BFT Emergence is a non-dilutive grant directed for deeptech startups to allow for the maximum financing of its R&D programs to reach the market. It is granted after a rigorous due diligence process of many months. The grant is part of the Deeptech plan financed by the France 2030 Program launched by the French State. Rosetta is a deeptech startup leading the way to precision medicine in oncology. We use spatial, multiomics (proteomics, metabolomics and lipidomics) and AI to predict the response to treatments in cancer patients and aid biopharma companies with patient stratification and biomarker discovery, and target validation.